Steve Garvey scores a rare GOP runoff spot in California’s U.S. Senate race
https://www.ocregister.com/2024/03/05/steve-garvey-scores-a-rare-gop-runoff-spot-in-californias-u-s-senate-race/
Mar 05, 2024 - Now it will be Adam Schiff vs. Steve Garvey in what could turn into a bitter runoff battle for the U.S, Senate seat long held by the late Democratic Sen. Dianne Feinstein, a contest sure to evoke many more baseball metaphors than any previous California campaign.
0
Rare Stock Picks In February 2024 - From 32 Discerning Analysts
https://seekingalpha.com/article/4675691-rare-stock-picks-in-february-2024-from-32-discerning-analysts?source=feed
Mar 05, 2024 - In our monthly Rare Stock Picks series, we're highlighting February 2024 investment picks. Click here for the list of February 2024 Buy recommendations.
0
RSV shots linked to slightly increased risk of rare neuro condition
https://seekingalpha.com/news/4074978-rsv-shots-linked-higher-risk-rare-neuro-condition?source=feed_sector_healthcare
Mar 02, 2024 - Newly introduced RSV vaccines from GSK (GSK) and Pfizer (PFE) slightly increase the risk of Guillain-Barre syndrome, a rare nervous system disorder. Read more here.
0
First Solar jumps on strong quarter, record backlog in rare bright spot for beaten-down renewable sector
https://www.cnbc.com/2024/02/28/first-solar-jumps-on-strong-quarter-record-backlog-in-rare-bright-spot-for-beaten-down-renewable-sector.html
Feb 28, 2024 - First Solar is one of the few companies that has weathered the sharp downturn in the solar sector.
0
Ramstad: A rare moment of political practicality — and agreement — at Minnesota Chamber
https://www.startribune.com/ramstad-a-rare-moment-of-political-practicality-and-agreement-at-minnesota-chamber/600344253/
Feb 17, 2024 - The national immigration debate is a mess, but Minnesota's legislative leaders understand its complexity and economic importance.
0
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
https://www.zacks.com/stock/news/2227421/ultragenyx-rare-q4-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2227421
Feb 16, 2024 - Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
0
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
0
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4670879-ultragenyx-pharmaceutical-inc-rare-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Feb 15, 2024 - Call End: Ultragenyx Pharmaceutical, Inc. (NASDAQ:NASDAQ:RARE)Q4 2023 Earnings Conference CallFebruary 15, 2024, 05:00 PM ETCompany ParticipantsJoshua Higa...
0
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
https://www.zacks.com/stock/news/2227212/compared-to-estimates-ultragenyx-rare-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2227212
Feb 15, 2024 - Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2227145/ultragenyx-rare-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227145
Feb 15, 2024 - Ultragenyx (RARE) delivered earnings and revenue surprises of 7.88% and 4.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0